Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Open Cagrilintide in the 3D analyzerAnalytical specification
| Empirical formula | C145H225N41O45 |
|---|---|
| Molecular weight | 3251.7 g/mol |
| Isoelectric point (pI) | 5.80 |
| Assay purity (HPLC) | 99.25% |
| Retention time | 5.75 min |
| Peak area / height | 11890 / 980 |
| Reference batch | CA-2026-N22 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | K-C-N-T-A-T-C-A-T-Q-R-L-A-N-F-L-V-H-S-S-N-N-F-G-A-I-L-S-S-T-N-V-G-S-N-T-Y |
Research characteristics
Amylin Agonism
Simulates native satiation control cycles
Synergy Target
Co-administered with GLP-1 options
Gastric Emptying
Fosters structured metabolic digestion
Satiety Control
Accelerates direct central signaling
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.
Orforglipron
Non-peptide oral small-molecule GLP-1 receptor agonist engineered for high bio-availability trials.